Survival and treatment of stage IV renal cell carcinoma in academic <i>vs</i> non-academic medical centers
Patients with mRCC treated at academic/research facilities experienced increased survival compared to patients treated at non-academic facilities, were more likely to be younger, carry private insurance, and come from a large metropolitan area. They also were significantly more likely to receive surgery and adjuvant immunotherapy.
Authors
- Marco Braaten
- Mohsin Mirza (ORCID: https://orcid.org/0000-0001-8399-7368)
- Jean‐Maríe Lehn (ORCID: https://orcid.org/0000-0001-8981-4593)
- Peter T. Silberstein (ORCID: https://orcid.org/0000-0003-1207-0287)
- Abubakar Tauseef (ORCID: https://orcid.org/0000-0002-4317-1868)
- Ali Bin Abdul Jabbar (ORCID: https://orcid.org/0000-0001-5145-8626)
- Muhammad Sohaib Asghar (ORCID: https://orcid.org/0000-0001-6705-2030)
- Abraham Mathews
- Bob Weng (ORCID: https://orcid.org/0009-0003-0859-7251)
- Reid Morrissey
Institutions
- Creighton University (US)
- Mayo Clinic (US)
Publication Details
- Journal
- World Journal of Nephrology
- Published
- 2025-04-08
- DOI
- https://doi.org/10.5527/wjn.v14.i2.103923
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00